Pfizer (PFE) Closes 2025 on Solid Note, Returns $9.8B to Shareholders

Pfizer Inc. (NYSE:PFE) is included among the Dividend Champions, Contenders, and Challengers List: 15 Highest Yielding Stocks.

Pfizer Inc. (NYSE:PFE) reported its Q4 2025 results on February 3. The company posted revenue of $17.56 billion, falling slightly by 1.1% from a year earlier. On the earnings call, Chairman and CEO Albert Bourla asserted that the company closed out 2025 on a strong footing, noting that execution throughout the year came in ahead of its financial commitments. Pfizer beat expectations on both revenue and adjusted diluted EPS and returned $9.8 billion to shareholders through dividends.

Looking to 2026, Bourla laid out the company’s main priorities, which include getting more value out of recent acquisitions, advancing Pfizer’s obesity pipeline, and expanding the use of artificial intelligence across the organization. He pointed to Seagen, Metsera, and Biohaven as some of the most important deals Pfizer has made in recent years, saying they have the potential to reshape the business. The focus now, he said, is on fully leveraging those portfolios and accelerating pipeline development.

Bourla also highlighted progress in Pfizer’s obesity program, noting encouraging results from the VESPER-3 study of its ultra-long-acting, next-generation injectable GLP-1 receptor agonist, previously known as MET-097i.

Chief Financial Officer David Denton added that full-year 2025 revenue came in at $62.6 billion, down from $63.6 billion the year before, reflecting a 2% operational decline. He emphasized that excluding COVID-19 products, operational revenue grew 6% for the year. Denton also said adjusted gross margins expanded to 76%, landing right where the company expected.

Pfizer Inc. (NYSE:PFE) operates as a research-driven global biopharmaceutical company, developing and commercializing medicines across oncology, primary care, and specialty areas for patients around the world.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Unstoppable Dividend Stocks to Buy According to Analysts and 13 Best Long Term Low Risk Stocks to Buy Now

Disclosure: None.